PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24680370-9 2014 In addition, this study found that paeonol down-regulated the transgelin 2-mediated paclitaxel resistance by reducing the expressions of P-gp, MRP1, and BCRP in MCF-7/PTX cells. Paclitaxel 84-94 ATP binding cassette subfamily C member 1 Homo sapiens 143-147 25647149-11 2015 The effects of paclitaxel on the multidrug resistance 1 (MDR1), MRP1 and breast cancer resistance protein (BCRP) gene expression were not significant in the MCF10AT cell lineage. Paclitaxel 15-25 ATP binding cassette subfamily C member 1 Homo sapiens 64-68 26012295-4 2015 Expression of Survivin and MRP were detected in 31 patients of NPC with paclitaxel resistance and 20 patients of NPC without paclitaxel resistance. Paclitaxel 72-82 ATP binding cassette subfamily C member 1 Homo sapiens 27-30 26012295-4 2015 Expression of Survivin and MRP were detected in 31 patients of NPC with paclitaxel resistance and 20 patients of NPC without paclitaxel resistance. Paclitaxel 125-135 ATP binding cassette subfamily C member 1 Homo sapiens 27-30 26012295-16 2015 The positive of MRP were 87.1% (27/31) in NPC patients with paclitaxel resistance and 40.0% (8/20) in NPC patients without paclitaxel resistance, respectively. Paclitaxel 60-70 ATP binding cassette subfamily C member 1 Homo sapiens 16-19 26012295-16 2015 The positive of MRP were 87.1% (27/31) in NPC patients with paclitaxel resistance and 40.0% (8/20) in NPC patients without paclitaxel resistance, respectively. Paclitaxel 123-133 ATP binding cassette subfamily C member 1 Homo sapiens 16-19 26012295-18 2015 There were positive correlation between the expression of Survivin and MRP in NPC patients with Paclitaxel resistance. Paclitaxel 96-106 ATP binding cassette subfamily C member 1 Homo sapiens 71-74 21903448-3 2011 We demonstrated that down-regulation of MRP1 in MC3/5FU, a drug-resistant MEC cell line, by RNA interference increased the drug sensitivity of the cells to 5-fluorouracil, doxorubicin, pharmorubicin, bleomycin-A5, cis-platinum and taxol. Paclitaxel 231-236 ATP binding cassette subfamily C member 1 Homo sapiens 40-44 9738565-0 1998 Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. Paclitaxel 37-47 ATP binding cassette subfamily C member 1 Homo sapiens 173-176 15231674-9 2004 Notably, several KB-derived multidrug-resistant cell lines overexpressing P-gp170/MDR and MRP are resistant to vincristine, paclitaxel, and colchicine but not to BPR0L075. Paclitaxel 124-134 ATP binding cassette subfamily C member 1 Homo sapiens 90-93 11334731-3 2001 Overexpression of multidrug resistant protein (MRP) family members was observed in the RPMI-2650Ml cells, which were also much more invasive in vitro than the parental cell line or the paclitaxel-resistant variant. Paclitaxel 185-195 ATP binding cassette subfamily C member 1 Homo sapiens 18-45 11334731-3 2001 Overexpression of multidrug resistant protein (MRP) family members was observed in the RPMI-2650Ml cells, which were also much more invasive in vitro than the parental cell line or the paclitaxel-resistant variant. Paclitaxel 185-195 ATP binding cassette subfamily C member 1 Homo sapiens 47-50 11809106-6 2000 The non-responders to platinum or taxol based combination chemotherapy exhibited higher ratios of MDR1 and MRP expression than the responders (P < 0.05). Paclitaxel 34-39 ATP binding cassette subfamily C member 1 Homo sapiens 107-110 10405640-2 1999 Vinca alkaloids, paclitaxel and docetaxel are actively effluxed by P-glycoprotein and/or the MRP1. Paclitaxel 17-27 ATP binding cassette subfamily C member 1 Homo sapiens 93-97 19823672-4 2009 Coincubating cells with a sublethal concentration of paclitaxel in combination with each of 2,000 small molecule compounds from the National Cancer Institute Diversity Set Library, we identified a previously uncharacterized molecule, NSC23925, that inhibits Pgp1 and reverses MDR1 (Pgp1) but does not inhibit MRP or BCRP-mediated MDR. Paclitaxel 53-63 ATP binding cassette subfamily C member 1 Homo sapiens 309-312 10565860-8 1999 These cells also exhibited a drug resistance profile commensurate with the previously described MRP1 overexpressing phenotype, with resistance to Vinca alkaloids, epipodophyllotoxins, and anthracyclines; additional cross-resistance to paclitaxel (Taxol), mitoxantrone, and 5-fluorouracil was observed. Paclitaxel 235-245 ATP binding cassette subfamily C member 1 Homo sapiens 96-100 10565860-8 1999 These cells also exhibited a drug resistance profile commensurate with the previously described MRP1 overexpressing phenotype, with resistance to Vinca alkaloids, epipodophyllotoxins, and anthracyclines; additional cross-resistance to paclitaxel (Taxol), mitoxantrone, and 5-fluorouracil was observed. Paclitaxel 247-252 ATP binding cassette subfamily C member 1 Homo sapiens 96-100 7601572-11 1995 This study provides evidence that (a) altered cellular pharmacokinetics is related to MRP expression; (b) MRP-mediated phenotype is characterized by a specific pattern of cross-resistance, which does not involve taxol; and (c) verapamil may be effective in modulating the function of the MRP gene product. Paclitaxel 212-217 ATP binding cassette subfamily C member 1 Homo sapiens 106-109 9496382-0 1997 Differences in docetaxel and paclitaxel activity in resistant tumor cells which express MRP: need of comparative clinical trials in resistant patients. Paclitaxel 29-39 ATP binding cassette subfamily C member 1 Homo sapiens 88-91 9496387-0 1997 Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP) BACKGROUND: Multidrug resistance has been associated with expression of the multidrug resistance protein (MRP). Paclitaxel 48-58 ATP binding cassette subfamily C member 1 Homo sapiens 124-152 9496387-0 1997 Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP) BACKGROUND: Multidrug resistance has been associated with expression of the multidrug resistance protein (MRP). Paclitaxel 48-58 ATP binding cassette subfamily C member 1 Homo sapiens 154-157 8831715-7 1996 For example, lower levels of taxol resistance are associated with overexpression of MRP than with overexpression of P-glycoprotein. Paclitaxel 29-34 ATP binding cassette subfamily C member 1 Homo sapiens 84-87 9816180-3 1996 In the present study, the modulatory activity of the novel pyridine analogue PAK-104P on MRP-mediated resistance to doxorubicin and paclitaxel was investigated in two doxorubicin-selected human tumor cell lines [HT1080/DR4 (sarcoma) and HL60/ADR (leukemia)] and compared with the nonimmunosuppressive cyclosporine analogue PSC-833. Paclitaxel 132-142 ATP binding cassette subfamily C member 1 Homo sapiens 89-92 7601572-11 1995 This study provides evidence that (a) altered cellular pharmacokinetics is related to MRP expression; (b) MRP-mediated phenotype is characterized by a specific pattern of cross-resistance, which does not involve taxol; and (c) verapamil may be effective in modulating the function of the MRP gene product. Paclitaxel 212-217 ATP binding cassette subfamily C member 1 Homo sapiens 106-109 31908478-10 2019 Furthermore, miR-7-induced sensitization of breast cancer to paclitaxel/carboplatin is markedly reversed by restoration of MRP1 and BCL2. Paclitaxel 61-71 ATP binding cassette subfamily C member 1 Homo sapiens 123-127 7916458-3 1994 MRP-overexpressing SW-1573 cells are resistant to doxorubicin, daunorubicin, vincristine, VP-16, colchicine, and rhodamine 123, but not to 4"-(9-acridinylamino)methanesulfon-m-anisidide or taxol. Paclitaxel 189-194 ATP binding cassette subfamily C member 1 Homo sapiens 0-3 34365218-5 2021 Further, majority of the non-platinum drugs except irinotecan increased ERK1/2 activation in platinum-taxol resistant cells as observed by live-cell BRET assessment which were associated with p90RSK1/2 and BAD activation along with upregulation of multidrug transporter gene ABCC1 and cell survival genes like cyclin D1 and Bcl2. Paclitaxel 102-107 ATP binding cassette subfamily C member 1 Homo sapiens 275-280 33965541-1 2021 The high expression of multidrug resistance-associated protein 1 (MRP1) in cancer cells caused serious multidrug resistance (MDR), which limited the effectiveness of paclitaxel (PTX) in non-small cell lung cancer (NSCLC) chemotherapy. Paclitaxel 166-176 ATP binding cassette subfamily C member 1 Homo sapiens 23-64 33965541-1 2021 The high expression of multidrug resistance-associated protein 1 (MRP1) in cancer cells caused serious multidrug resistance (MDR), which limited the effectiveness of paclitaxel (PTX) in non-small cell lung cancer (NSCLC) chemotherapy. Paclitaxel 166-176 ATP binding cassette subfamily C member 1 Homo sapiens 66-70 33965541-1 2021 The high expression of multidrug resistance-associated protein 1 (MRP1) in cancer cells caused serious multidrug resistance (MDR), which limited the effectiveness of paclitaxel (PTX) in non-small cell lung cancer (NSCLC) chemotherapy. Paclitaxel 178-181 ATP binding cassette subfamily C member 1 Homo sapiens 23-64 33965541-1 2021 The high expression of multidrug resistance-associated protein 1 (MRP1) in cancer cells caused serious multidrug resistance (MDR), which limited the effectiveness of paclitaxel (PTX) in non-small cell lung cancer (NSCLC) chemotherapy. Paclitaxel 178-181 ATP binding cassette subfamily C member 1 Homo sapiens 66-70 33758505-10 2021 Moreover, NE-PTX+BEZ235 treatment increased apoptosis, decreased Pgp and ABCC1 expression, and reduced tumor weights compared to the single drug treatment and the control group. Paclitaxel 13-16 ATP binding cassette subfamily C member 1 Homo sapiens 73-78 31883360-6 2020 The knockout and the induction of ABCC1 significantly increased and decreased the sensitivity of melanoma cells to paclitaxel. Paclitaxel 115-125 ATP binding cassette subfamily C member 1 Homo sapiens 34-39 31156720-8 2019 Results: Treatment with Plk1 inhibitors markedly reduced the expression of MDR1, MRP1, and Plk1 in the paclitaxel-resistant cancer. Paclitaxel 103-113 ATP binding cassette subfamily C member 1 Homo sapiens 81-85 31867270-10 2019 In order to test this, we generated a paclitaxel-resistant TNBC cell line which demonstrated an elevated level of eIF4A along with increased levels of cancer stemness markers (ALDH activity and CD44), pluripotency transcription factors (SOX2, OCT4, and NANOG) and drug transporters (ABCB1, ABCG2, and ABCC1). Paclitaxel 38-48 ATP binding cassette subfamily C member 1 Homo sapiens 301-306 30521500-0 2018 LINC01118 Modulates Paclitaxel Resistance of Epithelial Ovarian Cancer by Regulating miR-134/ABCC1. Paclitaxel 20-30 ATP binding cassette subfamily C member 1 Homo sapiens 93-98 30521500-10 2018 CONCLUSIONS LINC01118 acted as an oncogene and modulated EOC paclitaxel sensitivity by regulating miR-134/ABCC1. Paclitaxel 61-71 ATP binding cassette subfamily C member 1 Homo sapiens 106-111 29072615-0 2017 The Novel Triazolonaphthalimide Derivative LSS-11 Synergizes the Anti-Proliferative Effect of Paclitaxel via STAT3-Dependent MDR1 and MRP1 Downregulation in Chemoresistant Lung Cancer Cells. Paclitaxel 94-104 ATP binding cassette subfamily C member 1 Homo sapiens 134-138 30001527-12 2018 MRP1 depletion increased the sensitivity of MCF-7/ADR cells to ADR, VCR and PTX, and this effect was attenuated following miR-199a inhibition or linc00518 overexpression. Paclitaxel 76-79 ATP binding cassette subfamily C member 1 Homo sapiens 0-4 29399166-7 2018 It was identified that the expression levels of Twist, TOPO IIalpha, MRP and P-gp were upregulated and LRP was downregulated in human breast cancer tissues, which was consistent with the expression of these proteins in the Taxol -resistant MCF-7 cell model. Paclitaxel 223-228 ATP binding cassette subfamily C member 1 Homo sapiens 69-72 27284014-4 2016 We determined that our established PTX-resistant cancer cells display ABCB1/ABCC1-associated cross-resistance to chemically different drugs such as 5-fluorouracil, docetaxel, and cisplatin. Paclitaxel 35-38 ATP binding cassette subfamily C member 1 Homo sapiens 76-81 29085518-9 2017 The TxR cells also exhibited an increased expression of MDR-related proteins including MDR1 and MRP-1, which led to a substantial increase (5.4-fold) of the paclitaxel efflux from TxR-cells. Paclitaxel 157-167 ATP binding cassette subfamily C member 1 Homo sapiens 96-101